<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471613</url>
  </required_header>
  <id_info>
    <org_study_id>CN102c</org_study_id>
    <nct_id>NCT01471613</nct_id>
  </id_info>
  <brief_title>Lithium, Cord Blood Cells and the Combination in the Treatment of Acute &amp; Sub-acute Spinal Cord Injury</brief_title>
  <official_title>Safety and Effect of Lithium, Umbilical Cord Blood Cells and the Combination in the Treatment of Acute and Sub-acute Spinal Cord Injury : a Randomized, Double-Blinded Placebo-Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Spinal Cord Injury Network</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Chengdu PLA General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>StemCyte, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>China Spinal Cord Injury Network</source>
  <brief_summary>
    <textblock>
      The trial is to investigate the safety and efficacy of oral lithium, intraspinal umbilical
      cord blood mononuclear cell transplant, and the combination in the treatment of acute and
      subacute spinal cord injury
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in AIS Motor and sensory scores and ASIA Impairment Scales in 48 weeks</measure>
    <time_frame>Week 0, 1, 2, 6, 14, 24 and 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Walking</measure>
    <time_frame>Week 2, 6, 14, 24, 48</time_frame>
    <description>Walking Index of Spinal Cord Injury (WISCI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Functional assessment</measure>
    <time_frame>Week 2, 6, 14, 24, 48</time_frame>
    <description>Spinal Cord Injury Measure (SCIM) Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locomotion</measure>
    <time_frame>Week 2, 6, 14, 24, 48</time_frame>
    <description>Kunming locomotor scales</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spasticity grade</measure>
    <time_frame>Week 2, 6, 14, 24, 48</time_frame>
    <description>Modified Ashworth Scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>Week 2, 6, 14, 24, 48</time_frame>
    <description>Numerical rating scales</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>Group C - Cord blood cell</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment, cord blood cell transplant and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group A - Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Conventional treatment and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B - Lithium Carbonate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment and lithium carbonate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D - Combination Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment, cell transplant and 6-weeks course of lithium carbonate</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Treatment</intervention_name>
    <description>Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury</description>
    <arm_group_label>Group C - Cord blood cell</arm_group_label>
    <arm_group_label>Group A - Control</arm_group_label>
    <arm_group_label>Group B - Lithium Carbonate</arm_group_label>
    <arm_group_label>Group D - Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lithium Carbonate Tablet</intervention_name>
    <description>250mg/tablet, administrated orally for 6 weeks.</description>
    <arm_group_label>Group B - Lithium Carbonate</arm_group_label>
    <arm_group_label>Group D - Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cord Blood Cell</intervention_name>
    <description>Cord blood mononuclear cell, 6.4 million viable cells, are transplanted into spinal cord at upper and lower edges of the injured site</description>
    <arm_group_label>Group C - Cord blood cell</arm_group_label>
    <arm_group_label>Group D - Combination Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet, orally administration of placebo for 6 weeks</description>
    <arm_group_label>Group C - Cord blood cell</arm_group_label>
    <arm_group_label>Group A - Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  either gender and 18-65 years old;

          -  acute or subacute traumatic spinal cord injury (defined as SCI resulting from an
             exteneral non-penetrating cause that occurred within 4 weeks);

          -  neurological status of ASIA A;

          -  neurological level between C5-T11;

          -  MRI shows injury site is within 3 vertebral level and necrotic focus, if exist, is
             less than 1/3 of the spinal cord diameter;

          -  professional judgment determinate that subjects need a spinal decompression surgery;

          -  subjects able to complete neurological examination;

          -  subjects have voluntarily signed and dated an informed consent form.

        Exclusion Criteria:

          -  penetration SCI such as gun-shoot, knife-cutting or SCI caused by non-traumatic
             conditions;

          -  spinal cord lesion exceeds three segments or necrotic focus with diameter larger than
             1/3 of the spinal cord;

          -  severe complications;

          -  significant medical diseases or infection;

          -  pregnant or lactating woman, or female of childbearing potential and who is unwilling
             to use an effective contraceptive method while enrolled in the study;

          -  unavailability of suitable umbilical cord blood cells;

          -  contraindication of lithium carbonate and/or spinal decompression surgery

          -  subject is currently participating in another study or has been taking any
             investigational drug within the last 4 weeks prior to screening;

          -  investigator suggests that the subject would not be suitable to participate this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hui Zhu, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chengdu PLA General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Treating Center of Spinal Cord Injury, Chinese PLA Chengdu Army Kunming General Hospital</name>
      <address>
        <city>Kunming</city>
        <state>Yunnan</state>
        <zip>650032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 12, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2011</study_first_posted>
  <last_update_submitted>January 27, 2014</last_update_submitted>
  <last_update_submitted_qc>January 27, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>spinal cord injury</keyword>
  <keyword>umbilical cord blood cell</keyword>
  <keyword>cell transplant</keyword>
  <keyword>lithium carbonate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lithium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

